These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Orloff LM; Battle MA; Baer L; Ivanjack L; Pettit AR; Buttolph ML; Jenike MA Am J Psychiatry; 1994 Mar; 151(3):441-2. PubMed ID: 8109659 [TBL] [Abstract][Full Text] [Related]
11. Outcome of additional behaviour therapy including treatment discontinuation for fluvoxamine non-responders with obsessive-compulsive disorder. Nakatani E; Nakagawa A Psychother Psychosom; 2008; 77(6):393-4. PubMed ID: 18716426 [No Abstract] [Full Text] [Related]
12. [The difference between obsessive-compulsive disorder in adolescence and in adults]. Rabe-Jabłońska J Przegl Lek; 2001; 58 Suppl 3():11-4. PubMed ID: 11603169 [No Abstract] [Full Text] [Related]
13. Obsessive-compulsive disorder. Veale D; Roberts A BMJ; 2014 Apr; 348():g2183. PubMed ID: 24709802 [No Abstract] [Full Text] [Related]
14. Obsessive compulsive disorder is not an anxiety disorder. Montgomery SA Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():57-62. PubMed ID: 8254154 [No Abstract] [Full Text] [Related]